Cognitive Endpoint Data Quality in CNS Trials

Enhancing Signal Detection in CNS Trials

Cognitive Impairment in Oncology

Addressing CNS Clinical Trial Rater Shortages | Enabling New Raters to Gain Needed Qualifications

The Future of Alzheimer’s Disease Clinical Trials | Interview with Kaycee Sink, MD, MAS

Sedatives Effects on Cognition & Fatigue in Different Indications | Sleep Related Clinical Trials

Transforming Memory Tests: Lila App & the International Shopping List Test

Rater Performance Central Monitoring (RPCM) Programs in Early Symptomatic Alzheimer Disease Trials

Evidence that Amyloid Accumulation precedes ACh Neuronal Loss | ADPD Symposium Summary #Alzheimers

Reduce rater burden & increase efficiencies in Rare Disease trials | Rater Academy model explained

Schizophrenia Trials: Placebo Response vs. Practice Effects | Cogstate Digital Tests | ISCTM Poster

Reducing placebo response in Rare Disease clinical trials

Using Indication Specific Outcome Measures in Rare Disease Clinical Trials | Rett Syndrome Approval

Relationships between Alzheimers Biomarkers & Cogstate Cognitive Tests

Sensitivity of the Cogstate Brief Battery (CBB) to Mild Cognitive Impairment and Alzheimer’s Disease

Using Cogstate Digital Tests to Identify Cognitive Impairment in Alzheimer’s Disease Clinical Trials

Self-Administered Smartphone-based & Memory Assessment | AAIC 2023 Poster Data on Lila

Bring-Your-Own-Device Trial Feasibility with Cogstate Brief Battery (CBB) | AAIC 2023 Poster

Remote Preclinical Alzheimer’s Cognitive Composite (PACC) | Reliable & Valid for Clinical Trials

CDR-SB: Improved Sensitivity to Treatment Efficacy in Future Alzheimer's Disease Clinical Trials

Enhance Clinical Trial Data Quality & Reduce Burden | Central Rating Explained

Case Study: Measuring Neurocognitive Effects of Oncology Treatments in Pediatrics

Case Study: Selecting the Appropriate Patients for Global Alzheimer’s Disease Programs

Safety Monitoring System for Real Time Detection of CNS Adverse Events in Alzheimer's Disease Trials

Computer vs Smartphone-Administered Versions of the Cogstate Brief Battery | ADPD 2023 Poster

FY23 Half Year Results | Cogstate Investor Webcast

Neuroscience Consulting Opportunities Supporting Clinical Research | Cogstate LEADs

Case Study | Demonstrating Cognitive Safety of NMDA Modulator Antidepressant Medications

Remote Assessments in Alzheimer's Disease | Remote vs In-person data from PACC & CDR-SB | CTAD

Rater Perspectives on Applied Training of Cognitive Clinical Outcome Assessments (COAs) | AAIC 2022

Cogstate Investor Webcast | Full Year 2022 Results

Case Study: CAR T-Cell Therapy | Cognitive Safety | Cogstate

User Led Design of a Self-Administered Smartphone-based Learning & Memory Assessment | AAIC 2022

Detection of Mild Cognitive Impairment (MCI) | In-Clinic & Remote Cognitive Assessments | AAIC 2022

Dementia with Lewy Bodies | Disease-Specific Global Clinical Rating Scales | ADPD 2022 Poster

Dementia with Lewy Bodies | Composite Cognitive Outcome Measure | ADPD

FY22 Half Year Results | Cogstate Investor Webcast

Increase Rater Training Efficiency for Rare Disease Clinical Trials | NORD 2021 Poster

CTAD Recap | Trends in AD Drug Development

Parkinson's Disease Clinical Trial Services and Resources

Validity and Sensitivity of the Cogstate Brief Battery | ADNI3 | AD/PD 2021

FY21 Half Year Results | Cogstate Investor Webcast

Central Rating | Basics and Benefits for Rare Disease Clinical Trials

Designing Computerized Test Batteries for Clinical Trials

Cognitive Assessments as Efficacy Outcome Measures

Cognitive Assessments as Safety Outcome Measures

Using Cognitive Assessments to Guide Decision Making - Part Two

Using Cognitive Assessments to Guide Decision Making - Part One

Cogstate and Eisai Global Partnership | Early Identification of Alzheimer's Disease

June Quarter FY20 Business Update | Cogstate

First Half FY20 Business Update | Cogstate

FY20 Financial Results | Cogstate Investor Webcast

Initial Exploration of a Brain Age Score | Computerized Cognitive Assessments

Remote Cognitive Assessment Considerations and Capabilities for Clinical Trials | Cogstate

C3 Computerized Cognitive Battery | Results from A4 Study Baseline Data

Clinical Trials for Cognitive Impairment Associated with Schizophrenia - Cogstate Battery

Clinical Outcome Assessments for Clinical Trials in Rare Tauopathies

Measuring Cognition in Pediatric Oncology Clinical Trials

Computerized Cognitive Assessments: Cogstate Brief Battery

Cognitive Change Associated with Anesthesia and Surgery